These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25409334)

  • 21. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes.
    Jones RB; O'Connor R; Mueller S; Foley M; Szeto GL; Karel D; Lichterfeld M; Kovacs C; Ostrowski MA; Trocha A; Irvine DJ; Walker BD
    PLoS Pathog; 2014 Aug; 10(8):e1004287. PubMed ID: 25122219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Archin NM; Liberty AL; Kashuba AD; Choudhary SK; Kuruc JD; Crooks AM; Parker DC; Anderson EM; Kearney MF; Strain MC; Richman DD; Hudgens MG; Bosch RJ; Coffin JM; Eron JJ; Hazuda DJ; Margolis DM
    Nature; 2012 Jul; 487(7408):482-5. PubMed ID: 22837004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors.
    Archin NM; Keedy KS; Espeseth A; Dang H; Hazuda DJ; Margolis DM
    AIDS; 2009 Sep; 23(14):1799-806. PubMed ID: 19590405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
    Li P; Kaiser P; Lampiris HW; Kim P; Yukl SA; Havlir DV; Greene WC; Wong JK
    Nat Med; 2016 Jul; 22(7):807-11. PubMed ID: 27294875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation.
    Kuai Q; Lu X; Qiao Z; Wang R; Wang Y; Ye S; He M; Wang Y; Zhang T; Wu H; Ren S; Yu Q
    J Med Virol; 2018 Sep; 90(9):1478-1485. PubMed ID: 29704439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.
    Clutton G; Xu Y; Baldoni PL; Mollan KR; Kirchherr J; Newhard W; Cox K; Kuruc JD; Kashuba A; Barnard R; Archin N; Gay CL; Hudgens MG; Margolis DM; Goonetilleke N
    Sci Rep; 2016 Aug; 6():30749. PubMed ID: 27480951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.
    Vire B; de Walque S; Restouin A; Olive D; Van Lint C; Collette Y
    PLoS One; 2009 Sep; 4(9):e7085. PubMed ID: 19759901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
    Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells.
    Yin H; Zhang Y; Zhou X; Zhu H
    Mol Biol Rep; 2011 Nov; 38(8):5071-8. PubMed ID: 21181272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
    Lauffer BE; Mintzer R; Fong R; Mukund S; Tam C; Zilberleyb I; Flicke B; Ritscher A; Fedorowicz G; Vallero R; Ortwine DF; Gunzner J; Modrusan Z; Neumann L; Koth CM; Lupardus PJ; Kaminker JS; Heise CE; Steiner P
    J Biol Chem; 2013 Sep; 288(37):26926-43. PubMed ID: 23897821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CXCR4 Targeting Nanoplatform for Transcriptional Activation of Latent HIV-1 Infected T Cells.
    Vasukutty A; Pillarisetti S; Choi J; Kang SH; Park IK
    ACS Appl Bio Mater; 2024 Aug; 7(8):4831-4842. PubMed ID: 37586084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages.
    Ariffin JK; das Gupta K; Kapetanovic R; Iyer A; Reid RC; Fairlie DP; Sweet MJ
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1521-9. PubMed ID: 26711769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Manipulation of B-cell responses with histone deacetylase inhibitors.
    Waibel M; Christiansen AJ; Hibbs ML; Shortt J; Jones SA; Simpson I; Light A; O'Donnell K; Morand EF; Tarlinton DM; Johnstone RW; Hawkins ED
    Nat Commun; 2015 Apr; 6():6838. PubMed ID: 25913720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infection and replication of Tat- human immunodeficiency viruses: genetic analyses of LTR and tat mutations in primary and long-term human lymphoid cells.
    Chang LJ; Zhang C
    Virology; 1995 Aug; 211(1):157-69. PubMed ID: 7645208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
    Banga R; Procopio FA; Cavassini M; Perreau M
    J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent.
    Badia R; Grau J; Riveira-Muñoz E; Ballana E; Giannini G; Esté JA
    Antiviral Res; 2015 Nov; 123():62-9. PubMed ID: 26348004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.
    Archin NM; Espeseth A; Parker D; Cheema M; Hazuda D; Margolis DM
    AIDS Res Hum Retroviruses; 2009 Feb; 25(2):207-12. PubMed ID: 19239360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of 5' and 3' long terminal repeat promoter function in human immunodeficiency virus.
    Klaver B; Berkhout B
    J Virol; 1994 Jun; 68(6):3830-40. PubMed ID: 8189520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.